PURPOSE: To test the feasibility of covalent loading of daunorubicin into oxidized porous silicon (OPS) and to evaluate the ocular properties of sustained delivery of daunorubicin in this system. METHODS: Porous silicon was heat oxidized and chemically functionalized so that the functional linker on the surface was covalently bonded with daunorubicin. The drug loading rate was determined by thermogravimetric analysis. Release of daunorubicin was confirmed in PBS and excised rabbit vitreous by mass spectrometry. Daunorubicin-loaded OPS particles (3 mg) were intravitreally injected into six rabbits, and ocular properties were evaluated through ophthalmic examinations and histology during a 3-month study. The same OPS was loaded with daunorubicin using physical adsorption and was evaluated similarly as a control for the covalent loading. RESULTS: In the case of covalent loading, 67 ± 10 μg daunorubicin was loaded into each milligram of the particles while 27 ± 10 μg/mg particles were loaded by physical adsorption. Rapid release of daunorubicin was observed in both PBS and excised vitreous (~75% and ~18%) from the physical adsorption loading, while less than 1% was released from the covalently loaded particles. Following intravitreal injection, the covalently loaded particles demonstrated a sustained degradation of OPS with drug release for 3 months without evidence of toxicity; physical adsorption loading revealed a complete release within 2 weeks and localized retinal toxicity due to high daunorubicin concentration. CONCLUSIONS: OPS with covalently loaded daunorubicin demonstrated sustained intravitreal drug release without ocular toxicity, which may be useful to inhibit unwanted intraocular proliferation.
PURPOSE: To test the feasibility of covalent loading of daunorubicin into oxidized porous silicon (OPS) and to evaluate the ocular properties of sustained delivery of daunorubicin in this system. METHODS: Porous silicon was heat oxidized and chemically functionalized so that the functional linker on the surface was covalently bonded with daunorubicin. The drug loading rate was determined by thermogravimetric analysis. Release of daunorubicin was confirmed in PBS and excised rabbit vitreous by mass spectrometry. Daunorubicin-loaded OPS particles (3 mg) were intravitreally injected into six rabbits, and ocular properties were evaluated through ophthalmic examinations and histology during a 3-month study. The same OPS was loaded with daunorubicin using physical adsorption and was evaluated similarly as a control for the covalent loading. RESULTS: In the case of covalent loading, 67 ± 10 μg daunorubicin was loaded into each milligram of the particles while 27 ± 10 μg/mg particles were loaded by physical adsorption. Rapid release of daunorubicin was observed in both PBS and excised vitreous (~75% and ~18%) from the physical adsorption loading, while less than 1% was released from the covalently loaded particles. Following intravitreal injection, the covalently loaded particles demonstrated a sustained degradation of OPS with drug release for 3 months without evidence of toxicity; physical adsorption loading revealed a complete release within 2 weeks and localized retinal toxicity due to high daunorubicin concentration. CONCLUSIONS:OPS with covalently loaded daunorubicin demonstrated sustained intravitreal drug release without ocular toxicity, which may be useful to inhibit unwanted intraocular proliferation.
Authors: Kyle Kovacs; Sushant Wagley; Matthew T Quirk; Olga M Ceron; Paolo A Silva; Ravinder J Singh; Hovhannes J Gukasyan; Jorge G Arroyo Journal: Am J Ophthalmol Date: 2012-02-04 Impact factor: 5.258
Authors: Elizabeth C Wu; Jennifer S Andrew; Lingyun Cheng; William R Freeman; Lindsey Pearson; Michael J Sailor Journal: Biomaterials Date: 2010-11-30 Impact factor: 12.479
Authors: M Santana; P Wiedemann; M Kirmani; D S Minckler; R Patterson; N Sorgente; S J Ryan Journal: Graefes Arch Clin Exp Ophthalmol Date: 1984 Impact factor: 3.117
Authors: Takeshi Iwase; Jie Fu; Tsunehiko Yoshida; Daisuke Muramatsu; Akiko Miki; Noriyasu Hashida; Lili Lu; Brian Oveson; Raquel Lima e Silva; Christopher Seidel; Ming Yang; Sheila Connelly; Jikui Shen; Bing Han; Mingsheng Wu; Gregg L Semenza; Justin Hanes; Peter A Campochiaro Journal: J Control Release Date: 2013-10-12 Impact factor: 9.776
Authors: Feiyan Ma; Kaihui Nan; SuNa Lee; James R Beadle; Huiyuan Hou; William R Freeman; Karl Y Hostetler; Lingyun Cheng Journal: Eur J Pharm Biopharm Date: 2014-12-13 Impact factor: 5.571